The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

BACKGROUND: Preliminary data suggests a potential decreased benefit of docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with abiraterone acetate, a novel androgen synthesis inhibitor (ASI). CALGB 90401 (Alliance), a phase 3 trial of mCRPC patients trea...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Aggarwal, Rahul, Halabi, Susan, Kelly, William Kevin, George, Daniel, Mahoney, John F., Millard, Frederick, Stadler, Walter M., Morris, Michael J., Kantoff, Philip, Monk, J. Paul, Carducci, Michael, Small, Eric J.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2013
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3795898/
https://ncbi.nlm.nih.gov/pubmed/23913744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28285
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة